Business Description

Coloplast A/S designs to market and manufactures medical products. It has three segments: Interventional Urology and Chronic Care. The Interventional Urology segment includes the sale of urological products. Wound and Skin Care covers the sale of skin and wound care products. The Chronic Care segment includes the sale of continence products and ostomy products.  Aage Louis-Hansen founded the company in 1954 with Johanne Louise Hansen. The company is based in Humlebaek in Denmark.

Key Financials

Revenue (US$ Mn)

• US$ 3,066 Mn was the annual revenue generated by Coloplast A/S in 2020
• Coloplast A/S ‘s annual revenue for 2019 was US$ 2,716 Mn, a -2.78% decrease from 2018
• From 2017’s annual revenues, Coloplast A/S registered a 7.43% increase in 2018, amounting to US$ 2,794 Mn
• Total revenue of US$ 2,601 Mn was generated in 2017 by Coloplast A/S

Operating Income (US$ Mn)

• Coloplast A/S ‘s operating income for 2020 was US$ 971 Mn, a 13.3% increase from 2019
• The operating income generated by Coloplast A/S in 2019 was US$ 857 Mn
• At a 7.5% increase from , Coloplast A/S ‘s operating income of US$ 865 Mn was indexed in 2018
• Coloplast A/S generated an operating income of US$ 805 Mn in 2017

Net Income (US$ Mn)

• Coloplast A/S ‘s net income for 2020 was US$ 762 Mn, a 14.96% increase from 2019
• The net income generated by Coloplast A/S in 2019 was US$ 662 Mn
• At a -0.77% decrease from , Coloplast A/S ‘s net income of US$ 603 Mn was indexed in 2018
• Coloplast A/S generated a net income of US$ 608 Mn in 2017

Operating Margin %

• Coloplast A/S ‘s operating margin for 2020 was 32%, a 0.32% increase from 2019
• The operating margin generated by Coloplast A/S in 2019 was 32%
• At a 0.32% increase from , Coloplast A/S ‘s operating margin of 31% was indexed in 2018
• Coloplast A/S generated an operating margin of 31% in 2017

Gross Margin %

• 69% was the gross margin generated by Coloplast A/S in 2020
• Coloplast A/S ‘s gross margin for 2019 was 68%, a 0.44% increase from 2018
• From 2017’s gross margins, Coloplast A/S registered a 0.59% increase in 2018, amounting to 68%
• A gross margin of 67% was generated in 2017 by Coloplast A/S

SWOT Analysis

Strengths

Increased focus on R&D

Coloplast’s R&D activities are more important to maintain its leadership position. R&D focuses on improving the development process and complementing in-house skills with strong networks of external partners. Its strong patent portfolio is a clear sign of the company’s commitment to R&D. The company held exclusive licenses to over 300 patent technologies and 150 trademarks in FY2020. The company invested DKK659 million in R&D in FY2020, compared to DKK636million in FY2019. Coloplast’s increased investments in R&D have allowed it to reduce development time and launch new products and enhancements at regular intervals.

Get this premium content

The Premium data is Locked

Buy Now to Unlock Premium Data

Request Sample Data